Calamos Advisors LLC Sells 2,474 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Calamos Advisors LLC decreased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 25.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 7,404 shares of the company’s stock after selling 2,474 shares during the period. Calamos Advisors LLC’s holdings in Tarsus Pharmaceuticals were worth $201,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TARS. Jennison Associates LLC bought a new stake in Tarsus Pharmaceuticals in the first quarter valued at $48,380,000. Assenagon Asset Management S.A. bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at $28,904,000. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Tarsus Pharmaceuticals by 1,113.5% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock valued at $32,642,000 after buying an additional 824,000 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Tarsus Pharmaceuticals during the 1st quarter valued at $12,640,000. Finally, RTW Investments LP boosted its holdings in shares of Tarsus Pharmaceuticals by 9.4% during the 4th quarter. RTW Investments LP now owns 3,152,341 shares of the company’s stock valued at $63,835,000 after buying an additional 271,640 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TARS. Oppenheimer reaffirmed an “outperform” rating and issued a $63.00 price target (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. Barclays lifted their price target on Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, May 10th. Finally, HC Wainwright lifted their price target on Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.17.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $27.62 on Tuesday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $12.57 and a fifty-two week high of $42.50. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -5.79 and a beta of 1.06. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03. The business has a 50-day simple moving average of $26.47 and a two-hundred day simple moving average of $31.44.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. The firm had revenue of $40.81 million during the quarter, compared to analyst estimates of $31.30 million. During the same quarter in the prior year, the firm earned ($1.17) EPS. On average, analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.68 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.